Adult · ACLS

Tachycardia with a pulse

Three questions in order: is the tachycardia causing instability (cardiovert if so)? Is the QRS narrow or wide? Is the rhythm regular or irregular? Together they choose the treatment.

Guidelines: AHA 2020 with the 2023 update and confirmed 2025 changes; PALS 2020 with the 2025 pediatric updates

Reflects the AHA 2020 adult algorithms with the 2023 focused update, updated for the 2025 AHA Guidelines for CPR and ECC where the change could be confirmed; acute coronary syndromes follow the 2025 ACC/AHA guideline and stroke the 2026 AHA/ASA guideline. Pediatric content follows the AHA 2020 PALS algorithms with the 2025 AHA/AAP pediatric updates where confirmed.

Walk through it

One step at a time. Each step says what to do and why; at a decision, choose the branch that fits your patient. The map shows where you are.

The interactive walk needs JavaScript. Every step is listed below.

Every step at once
  1. Start

    Is the rate appropriate for the patient?

    • A tachyarrhythmia usually runs at 150/min or more.
    • Sinus tachycardia is a response: treat its cause, never cardiovert it.

    Why: Below about 150/min a primary arrhythmia rarely causes instability; a fast sinus rate is usually the heart answering fever, pain, bleeding or hypoxia.

    Then: Identify and treat the underlying cause

  2. Do

    Identify and treat the underlying cause

    • Airway, oxygen if hypoxemic, monitor, BP, SpO₂, IV access.
    • 12-lead ECG if available.

    Why: The 12-lead is the best evidence for what the rhythm is. Record it before a drug or a shock changes it, if the patient allows the time.

    Then: Is the tachycardia causing hypotension, altered mental status, shock, ischemic chest pain or acute heart failure?

  3. Decide

    Is the tachycardia causing hypotension, altered mental status, shock, ischemic chest pain or acute heart failure?

    Why: A fast rate cuts diastolic filling time and coronary perfusion. If perfusion is failing, the fastest reliable fix is electricity, not drugs.

  4. Then

    Synchronized cardioversion

    • Sedate if possible; do not delay for it if the patient is crashing.
    • Energy: follow the device. Atrial fibrillation and flutter: at least 200 J biphasic (2025). Regular narrow and monomorphic VT: commonly 100 J to start.
    • Regular narrow rhythm: adenosine may be tried while preparing.
    • Polymorphic VT: defibrillate (unsynchronized).

    Why: Synchronization times the shock to the R wave so it does not fall on the vulnerable T wave and cause VF. Polymorphic VT is too irregular to synchronize to, so it is treated like VF.

    Drugs: Adenosine

    Rhythm: AV nodal re-entrant tachycardia (AVNRT)

    Walk electrical therapy

  5. Decide

    Is the QRS wide (0.12 s or more)?

    Why: Width tells you where the rhythm comes from. Narrow means it uses the normal conduction system (supraventricular). Wide means ventricular, or supraventricular with a block or an accessory pathway; treat it as VT until proven otherwise.

  6. Decide

    Wide: is it regular and monomorphic?

    Why: Regular and monomorphic is most often VT. Irregular and wide is AF with aberrancy, pre-excited AF or polymorphic VT, and each of those has a dangerous wrong answer.

    Rhythm: Monomorphic ventricular tachycardia

  7. Then

    Antiarrhythmic infusion and expert consultation

    • Adenosine only if regular and monomorphic.
    • Procainamide 20–50 mg/min (stop at hypotension, QRS +50% or 17 mg/kg), or amiodarone 150 mg over 10 minutes.
    • Be ready to cardiovert if the patient becomes unstable.
    • Avoid calcium-channel blockers.

    Why: Verapamil or diltiazem given for presumed SVT that is actually VT can drop the blood pressure and cause arrest.

    Drugs: Procainamide, Amiodarone, Adenosine

  8. Then

    Irregular wide: think before you push

    • Pre-excited AF (very fast, varying width): no AV-nodal blockers; procainamide or cardioversion; expert help.
    • Polymorphic VT: if unstable or pulseless, defibrillate; magnesium for torsades with a long QT.
    • AF with a known bundle branch block: treat as AF.

    Why: Blocking the AV node in pre-excited AF leaves the accessory pathway as the only route, and the ventricles can degenerate into VF.

    Drugs: Procainamide, Magnesium sulfate

    Rhythm: Pre-excited atrial fibrillation (AF with WPW)

  9. Decide

    Narrow: is it regular?

    Why: Regular narrow tachycardia is usually re-entry through the AV node (AVNRT, AVRT), which vagal maneuvers and adenosine can break. Irregular narrow is usually AF, which they cannot.

  10. Do

    Vagal maneuvers, then adenosine

    • Modified Valsalva: strain, then lie flat with the legs raised.
    • Adenosine 6 mg rapid IV push with a flush; 12 mg if needed.
    • Record a rhythm strip during the dose.

    Why: Both slow AV-node conduction for a moment. A re-entry circuit that needs the node is interrupted; flutter or atrial tachycardia is not, but the pause shows the flutter waves.

    Drugs: Adenosine

    Rhythm: AV nodal re-entrant tachycardia (AVNRT)

    Then: Did it convert?

  11. Decide

    Did it convert?

    Why: Conversion proves the node was part of the circuit. No conversion makes atrial flutter or atrial tachycardia more likely.

  12. Then

    Monitor for recurrence

    • Recurrence: adenosine again, or a longer-acting AV-nodal blocker.
    • Record a 12-lead in sinus rhythm (look for pre-excitation).

    Why: A delta wave in sinus rhythm changes the long-term plan.

  13. Then

    Rate control and expert consultation

    • Beta-blocker or calcium-channel blocker (diltiazem or verapamil).
    • Treat the cause.

    Why: If the rhythm will not stop, slowing the ventricular response restores filling time and perfusion.

    Drugs: Beta-blockers (metoprolol, esmolol), Diltiazem and verapamil

  14. Then

    Irregular narrow: control the rate

    • Usually AF, flutter with variable block or MAT.
    • Beta-blocker or calcium-channel blocker.
    • Think about anticoagulation before rhythm control if AF has lasted 48 hours or more.
    • Expert consultation.

    Why: Cardioverting AF of uncertain duration can dislodge atrial clot; controlling the rate is safer in a stable patient.

    Drugs: Diltiazem and verapamil, Beta-blockers (metoprolol, esmolol)

    Rhythm: Atrial fibrillation with rapid ventricular response

The rhythms

At a glance

The whole algorithm on one page. Read from the top; a decision splits the path.

  1. Start

    Assess

    • Is the heart rate appropriate for the clinical condition? A tachyarrhythmia usually has a rate of 150/min or more.
  2. Do

    Identify and treat the underlying cause

    • Maintain the airway; assist breathing as needed.
    • Oxygen if hypoxemic.
    • Cardiac monitor, blood pressure and oximetry; IV access.
    • 12-lead ECG if available.
  3. Decide

    Is the tachyarrhythmia causing any of these?

    • Hypotension
    • Acutely altered mental status
    • Signs of shock
    • Ischemic chest discomfort
    • Acute heart failure

    Yes: unstable

    1. Do

      Synchronized cardioversion

      • Consider sedation.
      • If it is a regular narrow-complex rhythm, consider adenosine while preparing.
      • Polymorphic VT without a pulse, or too irregular to synchronize: defibrillate (unsynchronized).

    No: stable

    1. Decide

      Is the QRS wide (≥ 120 ms)?

      Wide

      1. Do

        Regular and monomorphic

        • Consider adenosine only if regular and monomorphic.
        • Consider an antiarrhythmic infusion.
        • Consider expert consultation.
      2. Do

        Irregular

        • Consider pre-excited AF (avoid AV-nodal blockers) or polymorphic VT; seek expert consultation.

      Narrow

      1. Do

        Regular

        • Vagal manoeuvres.
        • Adenosine.
        • Beta-blocker or calcium-channel blocker.
        • Consider expert consultation.
      2. Do

        Irregular

        • Usually AF, flutter with variable block or MAT: control the rate (beta-blocker or calcium-channel blocker) and consider anticoagulation; consider expert consultation.

Key points

Reading the rhythm

  • Treat a wide regular tachycardia as VT unless you are certain it is not.
  • Irregular, very fast and varying in width suggests pre-excited AF: adenosine, calcium-channel blockers, beta-blockers and digoxin can make it worse.
  • Sinus tachycardia is a response: treat the cause, do not cardiovert it.

Adenosine safely

  • Record a rhythm strip during the dose: transient block can reveal flutter or atrial tachycardia.
  • Warn the patient about brief chest discomfort and flushing.

Energies, doses and targets

WhatAs the guideline states itSource
Synchronized cardioversionRefer to your specific device's recommended energy level to maximize first-shock success.AHA 2020 adult algorithm
Synchronized cardioversion of AF (2025 change)Initial energy of at least 200 J with a biphasic defibrillatorAHA 2025 Guidelines, Part 9: Adult Advanced Life Support (as reported in the 2025 highlights)
Adenosine IVFirst dose 6 mg rapid IV push, followed by a normal saline flush; second dose 12 mg if requiredAHA 2020 adult algorithm
Procainamide IV (stable wide-QRS)20–50 mg/min until the arrhythmia is suppressed, hypotension ensues, QRS duration increases > 50% or a maximum of 17 mg/kg is given; maintenance 1–4 mg/min; avoid if prolonged QT or heart failureAHA 2020 adult algorithm
Amiodarone IV (stable wide-QRS)First dose 150 mg over 10 minutes; repeat as needed if VT recurs; follow with a maintenance infusion of 1 mg/min for the first 6 hoursAHA 2020 adult algorithm
Sotalol IV (stable wide-QRS)100 mg (1.5 mg/kg) over 5 minutes; avoid if prolonged QT. No longer listed in the 2025 algorithm.AHA 2020 adult algorithm; removed from the AHA 2025 algorithm

Mechanisms, cautions and pediatric doses: the drugs. Practise it: megacode cases.

Guidelines and sources

Reflects the AHA 2020 adult algorithms with the 2023 focused update, updated for the 2025 AHA Guidelines for CPR and ECC where the change could be confirmed; acute coronary syndromes follow the 2025 ACC/AHA guideline and stroke the 2026 AHA/ASA guideline.

Algorithms and doses follow the AHA 2020 Guidelines for CPR and ECC, adult algorithms (Part 3: Adult Basic and Advanced Life Support, Circulation 2020;142(suppl 2):S366–S468), checked for changes in:

  • 2023 AHA Focused Update on Adult Advanced Cardiovascular Life Support (Circulation 2024;149:e254–e273)
  • 2025 AHA Guidelines for CPR and ECC, Part 9: Adult Advanced Life Support

Changes in the 2025 guidelines reflected here:

  • Synchronized cardioversion of atrial fibrillation: an initial energy of at least 200 J with a biphasic defibrillator is now recommended, rather than a lower first shock.
  • The tachycardia algorithm refers to the device's recommended energy level rather than listing energies for each rhythm.
  • Intravenous access is preferred to intraosseous access as the first attempt in cardiac arrest.
  • Double sequential defibrillation and vector-change defibrillation for refractory VF remain of uncertain benefit.
  • Sotalol is no longer listed in the tachycardia algorithm; procainamide and amiodarone remain.
  • Routine calcium and sodium bicarbonate are not recommended in cardiac arrest; both are kept for specific causes.
  • After ROSC: titrate oxygen to an SpO₂ of 90–98%, keep the MAP at 65 mm Hg or more, and use deliberate temperature control (32–37.5 °C) for patients not following commands.
  • Polymorphic VT is treated as unstable and defibrillated.

Sources:

  1. Panchal AR, et al. Part 3: Adult Basic and Advanced Life Support: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2020;142(16 suppl 2):S366–S468.
  2. Perman SM, et al. 2023 American Heart Association Focused Update on Adult Advanced Cardiovascular Life Support. Circulation. 2024;149:e254–e273.
  3. Lavonas EJ, et al. 2023 American Heart Association Focused Update on the Management of Patients With Cardiac Arrest or Life-Threatening Toxicity Due to Poisoning. Circulation. 2023;148:e149–e184.
  4. Part 7: Adult Basic Life Support. 2025 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2025;152(16 suppl 2).
  5. Part 9: Adult Advanced Life Support. 2025 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2025;152(16 suppl 2):S538–S577.
  6. Part 10: Adult and Pediatric Special Circumstances of Resuscitation. 2025 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2025;152(16 suppl 2).
  7. Part 11: Post–Cardiac Arrest Care. 2025 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2025;152(16 suppl 2).
  8. Rao SV, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes. Circulation. 2025;151(13):e771–e862.
  9. Prabhakaran S, et al. 2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke (AHA/ASA). Stroke. 2026. doi:10.1161/STR.0000000000000513.

The full 2025 guideline text could not be opened when this page was drafted; the 2025 changes listed were confirmed from summaries of AHA's published 2025 algorithms and highlights. Drug doses are the 2020 algorithm doses, which those 2025 algorithms keep. All text and pictures here are original teaching material, not reproductions of AHA algorithms. Education only, not a treatment protocol.